TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression.

ABSTRACT:

Background

Breast cancer is the most common cancer in women worldwide. More than 70% of breast cancers are estrogen receptor (ER) alpha positive. Compared with ER alpha-negative breast cancer, which is more aggressive and has a shorter survival time, ER alpha-positive breast cancer could benefit from endocrine therapy. Selective estrogen receptor modulators, such as tamoxifen, are widely used in endocrine therapy. Approximately half of ER alpha-positive breast cancer patients will eventually develop endocrine resistance, making it a major clinical challenge in therapy. Thus, decoding the throughput of estrogen signaling, including the control of ER alpha expression and stability, is critical for the improvement of breast cancer therapeutics.

Methods

TRIM3 and ER alpha protei

SUBMITTER: Zhuang T 

PROVIDER: S-EPMC8991925 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature